FibroGen Inc. Files Q1 2025 10-Q
Ticker: KYNB · Form: 10-Q · Filed: May 12, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, financing
TL;DR
FibroGen's Q1 2025 10-Q is in. Check financials.
AI Summary
FibroGen Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including information related to its products and financing agreements. Key financial data and operational updates are presented for the first quarter of 2025.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and operational status of FibroGen Inc., crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, FibroGen faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial performance)
- 2025-03-31 — Balance Sheet Date (As of the end of the first quarter of 2025)
Key Players & Entities
- FIBROGEN INC (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- SAN FRANCISCO, CA (location) — Company's business and mailing address
- 415-978-1200 (phone_number) — Company's business phone number
- Falikang (product) — Mentioned product
- FibroGen International (company) — Subsidiary or related entity
- Novaquest Capital Management (company) — Involved in a Revenue Interest Financing Agreement
- Revenue Interest Financing Agreement (financial_instrument) — Financing agreement with Novaquest Capital Management
- Debt Financing Agreement (financial_instrument) — Mentioned financing agreement
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 12, 2025.
What is FibroGen Inc.'s business address?
FibroGen Inc.'s business address is 350 Bay Street, Suite 100 #6009, San Francisco, CA 94133.
Are there any specific products mentioned in the filing data?
Yes, 'Falikang' is mentioned as a product.
What type of financing agreements are referenced in the filing data?
The filing data references a 'Revenue Interest Financing Agreement' and a 'Debt Financing Agreement'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding FIBROGEN INC (KYNB).